EUCTR2007-007676-42-AT进行中(未招募)不适用
Acute STEMI treated with primary angioplasty and intravenous enoxaparin orUFH to lower ischemic and bleeding events at short- and long-term follow-up. - ATO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 910
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1- Be at least 18 years of age.
- •2- Has experienced continuous ischemic (cardiac) symptoms for at least 20 minutes.
- •3- Has onset of symptoms of qualifying acute MI within the past 24 hours, and planned for primary PCI. Patients presenting between 12 and 24 hours of symptom onset should still have an indication for primary PCI, i.e. persistent ischemic symptom and/or persistent or recurrent ST elevation
- •4- Has an ECG indicative of an acute STEMI showing:
- •= 2 mm ST elevation in 2 or more contiguous precordial ECG leads (anterior infarction); or
- •= 1 mm ST elevation in 2 or more contiguous limb ECG leads
- •(other infarction); or
- •New or presumably new left bundle branch block (LBBB)
- •5- Shock patients are eligible (but not patients with prolonged cardiac arrest)
- •6- Be willing to provide informed consent (informed consent may be provided by a legally authorized representative if the patient is not able to provide it).
- •7- Agree to comply with all protocol-specified procedures, including protocol-mandated follow-up
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1-Use of UFH or LMWH or any other anticoagulant agent (Vit K antagonists, fondaparinux, bivalirudin) within 48 hours prior to randomization
- •2-Thrombolytic therapy within the previous 48 hours
- •3-Known or suspected pregnancy in women of childbearing potential
- •4-History of hypersensitivity or contraindication to heparin or LMWH
- •5-Contraindication to primary PCI or any excessive bleeding risk (e.g. recent surgery also including punctions in the region of the spinal canal) or suspected active internal bleeding
- •6-Coexistent condition associated with a limited life expectancy at short term (e.g. advanced cancer)
- •7-Prolonged (> 10 minutes) cardiopulmonary resuscitation (CPR)
- •8-Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrolment in this trial
研究者
相似试验
进行中(未招募)
不适用
Acute STEMI treated with primary angioplasty and intravenous enoxaparin orUFH to lower ischemic and bleeding events at short- and long-term follow-up. - ATOEUCTR2007-007676-42-DEASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)910
已完成
不适用
Remote ischemic postconditioning in Acute myocardial infarctioAcute myocardial infarction.Acute transmural myocardial infarction of anterior wall, Acute transmural myocardial infarction of inferior wall, Acute transmural myocardial infarction of other sitesI21.0, I21IRCT2014101416229N4Cardiovascular Research Center of Tabriz University of Medical Sciences82
已完成
1 期
Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)Myocardial InfarctNCT01179776Thrombologic ApS16
已完成
不适用
Efficacy and Safety Study of Deferred Stenting in Patients With STEMIST-segment Elevation Myocardial InfarctionNCT02324348Korea University Anam Hospital114
已完成
不适用
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI Study)ISRCTN44258879niversity of Ottawa Heart Institute (Canada)170
